Takeda Pharmaceutical Logo
JP3463000004
853849
4502.T

Takeda Pharmaceutical

Caricamento quotazioni...

Previsioni

Acquista
  4
Mantieni
  1
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Takeda gets FDA priority review for zasocitinib in plaque psoriasis

    The FDA accepted Takeda's new drug application for zasocitinib under priority review with a target action date in Q1 2027 for adults with moderate-to-severe plaque psoriasis. Phase 3 trials showed strong efficacy (around 70% achieving clear or almost clear skin at week 16 versus ~11% for placebo) and statistical superiority to deucravacitinib on complete skin clearance. Approval, label restrictions, tolerability signals and payer access will determine commercial uptake and real-world revenue potential. » Altro su finance.yahoo.com


  • Takeda refocuses on upcoming launches after pipeline investments

    Takeda outlines a two-stage strategy emphasizing heavy pipeline investment and imminent launches (Horizon One), followed by a growth phase (Horizon Two). ORZEYFUL, the orexin agonist for narcolepsy type 1, received FDA approval and is awaiting DEA scheduling ahead of a planned US launch later this year. The selective TYK2 inhibitor zasocitinib has a PDUFA date of 13 March 2027 and is cited with peak sales potential of $3–6 billion for psoriasis/psoriatic arthritis; additional data on inflammatory bowel disease are expected by the end of fiscal 2024. R&D chief Andy Plump is retiring, Julie Kim is expected to shape future strategy; a more detailed update is scheduled for the capital markets day on 11 December in Tokyo. » Altro su de.investing.com


  • Takeda: FDA accepts application for psoriasis drug Zasocitinib for priority review

    The FDA has accepted Takeda’s New Drug Application for Zasocitinib (TAK-279) to treat moderate-to-severe plaque psoriasis for priority review; the PDUFA target date is Q1 2027. The EMA has also accepted the marketing application. The submission is supported by two phase III trials in which around 70% of patients achieved nearly clear skin after 16 weeks; key endpoints were met and no new safety signals emerged. Takeda does not expect the submission to have a material impact on consolidated financial guidance for the fiscal year ending 31 March 2027. » Altro su de.investing.com


  • Takeda receives FDA approval for blood cancer drug Mimrylo

    The FDA has approved Mimrylo (active ingredient rusfertid) from Takeda for the treatment of erythrocytosis in adults with polycythaemia vera. The decision is based on the phase‑III VERIFY study with 293 patients, in which 76.9% of treated patients showed a clinical response between weeks 20 and 32 and reduced hematocrit levels, fewer phlebotomies, and relief of fatigue were documented. Mimrylo is administered once weekly subcutaneously; common adverse events were injection‑site reactions (56%) and anemia (16%). Takeda holds the exclusive global development and commercialization rights and does not expect an impact on consolidated guidance for the fiscal year. » Altro su de.investing.com


  • Takeda receives FDA approval for narcolepsy drug Orzeyful

    The FDA has approved Orzeyful (Oveporexton) from Takeda for the treatment of narcolepsy type 1 in adults. Orzeyful is an oral orexin receptor-2 agonist; the approval is based on two phase‑III studies (FirstLight, RadiantLight) showing significant improvements in daytime sleepiness, cataplexy and quality of life. Common adverse effects were insomnia, increased urination and increased salivation; the drug is contraindicated with strong CYP3A inhibitors. The DEA is still reviewing the controlled-substance scheduling; once that process is complete, dispensing will be via specialty pharmacies. Takeda does not expect a material impact on consolidated financial guidance for the fiscal year ending 31.03.2027. » Altro su de.investing.com

Nel 2026, Takeda Pharmaceutical ha già distribuito 0,54 € di dividendi. L'ultimo pagamento è avvenuto a giugno.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Takeda Pharmaceutical ha registrato ricavi pari a 6,65 Mld € e un utile netto di 1,08 Mld €
(EUR) settembre 2026
YoY
Ricavi 6,65 Mld 3,82%
Utile lordo 4,45 Mld 5,59%
Utile netto 1,08 Mld 1686,78%
EBITDA 1,83 Mld 7,39%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
62,58 Mld €
Numero di azioni
1,6 Mld
Massimo/minimo a 52 settimane
39,70 € - 25,16 €
Rendimento da dividendo
2,77%
Dividendi TTM
1,10 €
Prossimo dividendo
0,58 €
Beta
0,09
Rapporto P/E
28,48
Rapporto PEG
0,03
Rapporto P/B
1,47
Rapporto P/S
2,37

Profilo aziendale

Takeda Pharmaceutical Company Limited si occupa di ricerca, sviluppo, produzione, commercializzazione e out-licensing di prodotti farmaceutici in tutto il mondo. Offre prodotti farmaceutici nelle aree della gastroenterologia; dell'oncologia; delle neuroscienze; e delle malattie rare, come le malattie metaboliche rare e l'ematologia, e l'angioedema ereditario, oltre a terapie plasmaderivate e vaccini. L'azienda commercializza i propri prodotti con i marchi Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro e Alunbrig. Takeda Pharmaceutical Company ha accordi di licenza con Denali Therapeutics e Wave Life Sciences Ltd; accordi di collaborazione con Neurocrine Biosciences, Inc. e Rani Therapeutics LLC; accordi di licenza e ricerca con The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc. e Arrowhead Pharmaceuticals Inc.; accordi di collaborazione per la ricerca con Arrowhead Pharmaceuticals Inc. e Ovid Therapeutics Inc.; una collaborazione con Evox Therapeutics Ltd., nonché un accordo di licenza con ProThera Biologics Inc. Ha inoltre alleanze strategiche con Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; e Anima Biotech. Takeda Pharmaceutical Company Limited è stata fondata nel 1781 e ha sede a Tokyo, in Giappone.

Nome
Takeda Pharmaceutical
CEO
Julie So-Young Kim
Sede centrale Tokyo, os
Giappone
Sito web
Settore
SanitĂ 
Industria
Prodotti farmaceutici
Quotazione in borsa
04/01/2000
Dipendenti 47.029

Simboli di borsa

Borsa Simbolo
Japan Exchange Group
4502.T
Pnk
TKPHF
Frankfurt
TKD.F
DĂĽsseldorf
TKD.DU
Hamburg
TKD.HM
London
0RN3.L
MĂĽnchen
TKD.MU
Wien
TKD.VI
🍪

Parqet  usa i cookie. Scopri di più